XML 75 R53.htm IDEA: XBRL DOCUMENT
v3.25.4

Collaboration Agreements and Research and Development Funding Arrangement (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Jun. 30, 2016 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023 | Mar. 31, 2024 | Oct. 31, 2023 | Oct. 31, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Research and development |  | $ 3,132 | $ 4,543 | $ 4,845 |  |  |
Additions |  | 320 |  |  |  |  |
Research and development funding liability (Note 5) |  | 43 | 58 |  |  |  |
PCV Agreement |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Additions | $ 200 |  |  |  |  |  |
Merck | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Proceeds from option exercise fee |  |  |  |  |  |  | $ 250
Research and development |  | 407 | 390 | 184 |  |  |
Cost recovery |  | 24 | 109 | $ 102 |  |  |
Blackstone Life Sciences (Blackstone) | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Research and development |  | 340 | 267 |  |  |  |
Funding amount |  |  |  |  | $ 750 |  |
Upfront payment |  |  |  |  | $ 750 |  |
Research and development funding liability (Note 5) |  | $ 43 | $ 58 |  |  |  |
Immatics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  | $ 120 |

X
- Definition Collaborative Arrangement, Funding Amount + References No definition available. + Details
Name: | mrna_CollaborativeArrangementFundingAmount
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product + References No definition available. + Details
Name: | mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Proceeds From Option Exercise Fee + References No definition available. + Details
Name: | mrna_ProceedsFromOptionExerciseFee
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Recovery Of Costs, Capital Expenditures + References No definition available. + Details
Name: | mrna_RecoveryOfCostsCapitalExpenditures
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research And Development Liability, Current + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentLiabilityCurrent
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrna_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrna_BlackstoneLifeSciencesBlackstoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrna_ImmaticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |